S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 2: Supportive therapy of EN in the acute and post‐acute stages
Summary Stevens‐Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug‐induced, acute life‐threatening diseases of skin and mucosae. SJS and TEN are nowadays considered as variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN)...
Saved in:
Published in: | Journal der Deutschen Dermatologischen Gesellschaft Vol. 22; no. 11; pp. 1576 - 1593 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Germany
Wiley Subscription Services, Inc
01-11-2024
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Summary
Stevens‐Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug‐induced, acute life‐threatening diseases of skin and mucosae. SJS and TEN are nowadays considered as variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline “Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis)” was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence‐based framework to support clinical decision‐making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and of patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical specialties involved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. The second part is concerned with the topics of supportive therapy in the acute phase of EN and outpatient follow‐up treatment. |
---|---|
Bibliography: | DGP – German Society of Nursing Science DGU – German Society for Urology DeGPT – German‐speaking Society for Psychotraumatology DGGG – German Society for Gynecology and Obstetrics DGKCH – German Society for Pediatric Surgery DOG – German Society of Ophthalmology DGKJ – German Society of Pediatrics and Adolescent Medicine Maren Paulmann and Ruben Heuer contributed equally to the publication. Participating societies The guideline is valid until December 31, 2027 DGMP – German Society for Medical Psychology Maja Mockenhaupt and Alexander Nast contributed equally to the publication. BVDD – Professional Association of German Dermatologists DGPRÄC – German Association of Plastic, Reconstructive and Aesthetic Surgeons DGI – German Society for Infectious Diseases German Pain Society AWMF registry number DGAI – German Society of Anesthesiology and Intensive Care Medicine : DGAKI – German Society for Allergology and Clinical Immunology DDG – German Dermatological Society 013‐103 Validity of Guideline DGV – German Society for Burn Treatment ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Instructional Material/Guideline-3 content type line 23 |
ISSN: | 1610-0379 1610-0387 1610-0387 |
DOI: | 10.1111/ddg.15516 |